Henry Schein, Inc.
HSIC Healthcare Medical Distribution
Henry Schein, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.2 billion, up 4.03% from fiscal 2024. In the quarter to June 2026, revenue grew 6.73%, EPS grew 16.9%, free cash flow grew 140.9% and total debt rose 15.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow HSIC
Henry Schein, Inc. (HSIC) Revenue
Henry Schein, Inc.'s revenue for fiscal 2025 was $13.2B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $13.6B. Over the past ten years it has ranged from $8.9B (fiscal 2017) to $13.2B (fiscal 2025) — the current reading is the highest in ten years. Henry Schein, Inc. ranks 4th of 10 Medical Distribution companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $13.2B | 4.03% |
| FY2024 | $12.7B | 2.71% |
| FY2023 | $12.3B | (2.44%) |
| FY2022 | $12.6B | 1.98% |
| FY2021 | $12.4B | 22.55% |
| FY2020 | $10.1B | 1.33% |
| FY2019 | $10.0B | 6.03% |
| FY2018 | $9.4B | 6.01% |
| FY2017 | $8.9B | (23.23%) |
| FY2016 | $11.6B | 8.86% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $3.5B | 2.67% |
| Mar 2026 | $3.4B | (2.01%) |
| Dec 2025 | $3.4B | 2.94% |
| Sep 2025 | $3.3B | 3.06% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MCK McKesson Corporation compare | $411.0B |
| COR Cencora, Inc. compare | $332.8B |
| CAH Cardinal Health, Inc. compare | $254.2B |
| HSIC Henry Schein, Inc. | $13.6B |
| ACH Accendra Health, Inc. compare | $2.6B |
| FOCL FocalTherics compare | $77.8M |
| COSM Cosmos Health Inc. compare | $73.7M |
| AHG Akso Health Group Sponsored ADR compare | $20.1M |
| HKPD Cellyan Biotechnology Co., Ltd compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on HSIC
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement